CIC
KLRS

Cornercap Investment Counsel’s Kalaris Therapeutics KLRS Stock Holding History

Cornercap Investment Counsel’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,846
Closed -$141K – 661
2023
Q3 		$141K Sell
2,846
-37
-1% -$2.52K 0.03% 522
2023
Q2 		$225K Buy
2,883
+1,166
+68% +$111K 0.04% 494
2023
Q1 		$156K Hold
1,717
– – 0.03% 523
2022
Q4 		$203K Sell
1,717
-239
-12% -$40.5K 0.04% 517
2022
Q3 		$355K Buy
1,956
+496
+34% +$77.3K 0.07% 431
2022
Q2 		$131K Buy
+1,460
New +$153K 0.02% 517

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Cornercap Investment Counsel's KLRS Position: Q4 2023 in Review

Cornercap Investment Counsel sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 2,846 shares — an estimated $141K sold.

Cornercap Investment Counsel first reported a position in KLRS in Q2 2022 and held it in 6 quarters. The position peaked at $355K in Q3 2022. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Cornercap Investment Counsel reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 2,846 Kalaris Therapeutics shares in Q4 2023, an estimated $141K.
  • Cornercap Investment Counsel first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 6 quarters.
  • Cornercap Investment Counsel's Kalaris Therapeutics position peaked at $355K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Cornercap Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.